ICAD: iCAD Inc. Consensus Target

Symbol and logo of brand iCAD Corp (ICAD)

The price trend visualization for iCAD, Inc. (ICAD) demonstrates the dynamics of a company developing AI systems for oncology diagnostics utilizing AWS clouds, where the indicator stands at 3.51. The business relies on the organic growth of its SaaS model and the integration of software into scanning equipment. However, competing with medtech behemoths and the risk of specialized algorithms losing value due to mass proliferation remain serious challenges.

Analyst Consensus Forecast: iCAD Corp (ICAD) for 07/04/2022 - 08/02/2025
Original product of iCAD, Inc.

This indicator represents the aggregated target price of the asset, reflecting the professional community's average expectation regarding the business's fair market valuation. Investors utilize expert price targets to determine growth potential, which is critical for iCAD, Inc. (ICAD), as the high accuracy of its AI breast cancer diagnostics enables the company to maintain pricing power within the medical sector.

Competing companies

Analyst Median Target beigene.com|Analyst Consensus Forecast HALO (Halozyme)|RVMD - Consensus Target|Ascentage - Analyst Consensus Forecast|CGON - Analyst Consensus Forecast|URGN: Analyst Consensus Forecast|Broker Consensus Forecast BCAX|PSNL (Personalis) - Analyst Consensus Forecast|Consensus Target Erasca Inc (ERAS)|Analyst Consensus Forecast DCTH|Analyst Consensus Forecast Y-mAbs Corp (YMAB)|Price Target Chart Aura Biosciences, Inc. AURA|CADL: Broker Consensus Forecast|Accuray - Analyst Consensus Forecast|SELLAS Life Sciences (SLS) - Consensus Target|ACTU: Analyst Consensus Forecast|Average Forecast Price Citius Oncology Inc (CTOR)|Price Target Chart TuHURA Biosciences Inc.|TARA: Fair Value Consensus|Consensus Target FATE (Fate Therapeutics)|WHWK (aadibio.com) - Fair Value Consensus|Analyst Consensus Forecast TCRX (TScan Therapeutics, Inc.)|CSBR - Consensus Target|XBIT: Consensus Target|CVM - Analyst Consensus Forecast|OS Therapies (OSTX) - Price Target Chart|Radiopharm Theranostics Ltd - Fair Value Consensus|ARTV (Artiva Biotherapeutics Inc.) - Analyst Consensus Forecast|Average Forecast Price Adlai Nortye Limited ANL|Analyst Consensus Forecast VERU|Analyst Median Target tempesttx.com|Analyst Consensus Forecast XLO (Xilio Therapeutics)|RENB - Consensus Target|Mural Bio - Analyst Consensus Forecast|KAPA - Analyst Consensus Forecast|OKUR: Analyst Consensus Forecast|Broker Consensus Forecast GDTC|Consensus Target CRIS|APLM: Fair Value Consensus|Analyst Consensus Forecast THAR|Analyst Median Target advanbiomed.com|Price Target Chart Genprex, Inc. GNPX|CLDI: Broker Consensus Forecast|Sunshine Biopharma - Analyst Consensus Forecast|Xenetic Biosciences (XBIO) - Consensus Target|SLRX (Salarius) - Consensus Target|PPBT - Analyst Median Target|AONC (American Oncology Network Inc) - Analyst Consensus Forecast|beigene.com (BGNE) - Analyst Median Target|Analyst Consensus Forecast CKPT|Consensus Target Elevation Oncology Inc. ELEV|Analyst Consensus Forecast IKNA (Ikena Oncology)|Analyst Consensus Forecast Notable Labs Corp NTBL|Viracta - Analyst Consensus Forecast|MOR (morphosys.com) - Broker Consensus Forecast|NAYA: Analyst Consensus Forecast|Consensus Target Ascentage Pharma Group International